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Background. The molecular mechanisms of renal injury and
fibrosis in proteinuric nephropathies are not completely eluci-
dated but the renin-angiotensin system (RAS) is involved. Idio-
pathic membranous nephropathy (MN), a proteinuric disease,
may progress to renal failure. Our aim was to investigate the
localization of RAS components in MN and their correlation
with profibrotic parameters and renal injury.
Methods. Renal biopsies from 20 patients with MN (11 with
progressive disease) were studied for the expression of RAS
components [angiotensin-converting enzyme (ACE) and an-
giotensin II (Ang II)] by immunohistochemistry. Transform-
ing growth factor- (TGF-) and platelet-derived growth fac-
tor (PDGF)-BB were studied by by in situ hybridization, and
myofibroblast transdifferentiation by -smooth muscle actin
(-SMA) staining.
Results. ACE immunostaining was elevated in tubular cells
and appeared in interstitial cells colocalized in -actin–positive
cells in progressive disease. Elevated levels of Ang II were
observed in tubules and infiltrating interstitial cells. TGF- and
PDGF mRNAs were up-regulated mainly in cortical tubular
epithelial cells in progressive disease (P 0.01) and correlated
with the myofibroblast transdifferentiation (r  0.8, P  0.01
for TGF-; r  0.6, P  0.01 for PDGF). Moreover, in serial
sections of progressive cases, the ACE and Ang II over-expres-
sion was associated with the tubular expression of these pro-
fibrogenic factors, and with the interstitial infiltration and myo-
fibroblast activation.
Conclusion. Intrarenal RAS is selectively activated in pro-
gressive MN. De novo expression of ACE at sites of tubulo-
interstitial injury suggests that the in situ Ang II generation
could participate in tubular TGF- up-regulation, epithelial-
myofibroblast transdifferentiation, and disease progression.
These results suggest a novel role of Ang II in human tubulo-
interstitial injury.
In recent years there has been growing evidence that
abnormal glomerular permeability to plasma proteins
and tubular traffic of filtered proteins can elicit an in-
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flammatory and fibrogenic response, mediated by diverse
chemokines and fibrogenic cytokines, that causes tubulo-
interstitial injury and a progressive decline in renal func-
tion [1]. The molecular mechanisms of renal injury and
fibrosis in chronic proteinuric nephropathies are not com-
pletely elucidated but the renin-angiotensin system (RAS)
is involved and seems to play a key role in progression
to fibrosis [2, 3]. Therapies directed to RAS inhibition,
such as angiotensin-converting enzyme inhibitors (ACEI)
and AT1 blockers, effectively limited or fully prevented
progression of renal disease in animal models and human
nephropathies [4, 5].
Idiopathic membranous nephropathy (MN) is a typical
progressive human proteinuric renal disease, especially in
cases with persistent nephrotic range proteinuria. We re-
cently demonstrated in human biopsy specimens from pa-
tients with progressive MN a tubular over-activation of
transcription factors [nuclear factor kappa B (NFB) and
activator protein-1 (AP-1)] and an over-expression of
proinflammatory [monocyte chemoattractant protein-1
(MCP-1), regulated upon activation, normal T cell ex-
pressed and secreted (RANTES), osteopontin] and pro-
fibrogenic [transforming growth factor- (TGF-), plate-
let-derived growth factor (PDGF)-BB] cytokines asso-
ciated to an interstitial accumulation of mononuclear cells
and an increase in myofibroblastic activity [6, 7]. Mono-
cytes/macrophages are attracted to sites of injury by che-
mokines and these same infiltrating cells will further
release inflammatory chemokines and cytokines, leading
to a vicious cycle perpetuating the pathways responsible
for progressive tubulointerstitial injury and fibrosis [8].
Angiotensin II (Ang II) has a pivotal role in the changes
in glomerular hemodynamics and permeability proper-
ties of the filtration barrier contributing to proteinuria;
however, in addition to these effects, Ang II has been
directly implicated in tubulointerstitial injury and fibrosis
acting as a local growth factor and directly influencing
tubulointerstitial changes [3, 9, 10]. Intrarenal activation
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of RAS seems to play a key role in this process and it may
be up-regulated by proteinuria, as it was demonstrated in
a recently published study in an animal model of intense
proteinuria and interstitial nephritis induced by protein
overload [11]. Moreover, evidence has been provided that
Ang II may induce activation of NFB in renal tubular
cells and vascular smooth muscle cells [12, 13].
There are few studies that have examined the localiza-
tion of RAS components in human chronic proteinuric
nephropathies such as MN. Therefore, we examined the
intrarenal localization of diverse components of RAS
and explored their potential functional correlation, par-
ticularly with profibrogenic cytokine expression and my-
ofibroblast transdifferentiation. Our working hypothesis
is that elevated local RAS during MN could be associated
to the tubulointerstitial fibrosis and, therefore, contrib-
ute to the progression of the disease.
METHODS
Human kidney MN specimens have been examined
from renal tissue of patients, as described in previous
communications [6, 7]. Kidney samples were obtained
by percutaneous renal biopsy from patients undergoing
diagnostic evaluation at the Division of Nephrology, Aus-
tral University, Valdivia, Chile. The renal biopsies from
20 patients with idiopathic MN were studied (11 with
progressive MN and 9 with non-progressive MN). The
classification of progressive MN was done based on the
presence of severe nephrotic syndrome (persistent mas-
sive proteinuria8 g/day for at least 6 months), intersti-
tial cell infiltration, and decrease of renal function at the
time of the biopsy or during the following months. The
9 non-progressive MN patients were also nephrotic (pro-
teinuria 3 g/day for less than 6 months), but without
interstitial cell infiltration and with stable renal function
at the time of the biopsy and during the long-term follow-
up. None of the patients were being treated with ACE
inhibitors or AT1 antagonist at the time of the biopsy,
and none of them had renal vein thrombosis.
Human control kidney specimens (N  5) were taken
from normal portions of renal tissue from patients who
underwent surgery because of localized renal tumors.
As control groups we also used some samples from pa-
tients with minimal change disease (MCD).
Light microscopy, immunohistochemistry, and
in situ hybridization
Paraffin-embedded sections were treated for each tech-
nique as described [6]. Morphology was evaluated by he-
matoxylin and eosin (H&E), periodic acid-Schiff (PAS),
and silver methenamine staining. Masson staining was
used to evaluate the presence of interstitial fibrosis.
For immunohistochemistry in paraffin-embedded tis-
sue, the following primary antibodies were employed:
anti-Ang II (rabbit antiserum, IHC 7002; Peninsula Lab-
oratories, San Carlos, CA, USA) used as described [14];
a rabbit polyclonal antibody we developed, and raised
against a synthetic peptide corresponding to the last 20
amino acids of the human ACE intracellular carboxyl-
terminal sequence (peptide 1258-1277, SLHRHSHGPQ
FGSEVELRHS) was used to localize immunoreactive
ACE as previously described [15, 16]. The antibody is
directed against an intracellular domain of the enzyme
and therefore recognizes the enzyme in its native, mem-
brane-bound form at the site of synthesis, and does not
cross-react with the plasma (circulating) enzyme, which
is truncated in its region during its release into the circu-
lation [15, 16]; specific biotinylated secondary antibodies,
followed by streptavidin-horseradish peroxidase (HRP)
conjugate (Dako Corp. Carpinteria, CA,USA), and re-
vealed with diaminobenzidine (DAB), were used. For all
staining, controls consisted of replacing the primary anti-
body with a nonspecific immunoglobulin G (IgG) of the
same species.
Cryostat sections (5 m thick) from tissue fragments,
frozen and kept in liquid nitrogen, were also used for
the detection of T lymphocytes CD4 (mouse monoclonal,
MT310; Dako Corp.) and T lymphocytes CD8 (mouse
monoclonal, DK25; Dako Corp.).
In situ hybridization (ISH) was performed as de-
scribed previously [6, 7]. Biotin-labeled human TGF-
and PDGF probes were purchased from R&D Systems
(Minneapolis, MN, USA). The specificity of the reaction
was confirmed by: (1) demonstrating the disappearance
of hybridization signal when RNAse (100g/mL) (Sigma
Chemical Co., St. Louis, MO, USA) was added in 0.05
mol/L Tris after the digestion with proteinase K; (2) the
use of a sense probe (R&D Systems); (3) using a negative
control (Plasmid DNA) (Dako Corp.); and (4) not using
a probe.
Immunohistochemistry coupled with ISH: This tech-
nique was performed to simultaneously detect -SMA–
positive cells by IHC and cells expressing TGF- by ISH
on the same biopsy section, as described previously [6].
Histochemistry quantification
The percentage and intensity of the labeled surface
area was evaluated by using a KS 300 Imaging System
3.0 (Zeiss). The degree of staining was calculated by the
ratio of suitable binary threshold image and the total
field area, integrating the intensity of the staining in the
specific areas. Readings performed in this way allowed
potential differences in the amount of total tissue exam-
ined to be avoided. For each sample, a mean value was
obtained by analysis of 20 different fields (40), exclud-
ing glomeruli and vessels. Quantification was done twice
in a blinded manner and the interassay variations were
not significant. The staining score is expressed as density/
mm2. This form of analysis, used to quantify immunohis-
tochemical assays, has been validated in previous publi-
cations by our group [7].
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Fig. 1. Expression of components of the re-
nin-angiotensin system (RAS) in idiopathic
membranous nephropathy (MN). Magnifica-
tion 400. Figure shows serial sections of two
representative cases. (A ) In contrast to that
observed in normal kidneys, in which angio-
tensin-converting enzyme (ACE) was weakly
expressed in the brush border of proximal tu-
bules, a marked up-regulation was noted in
some tubules, and (B, C ) ACE neoinduction
appeared in interstitial cells, mainly -actin–
positive cells. (D ) Angiotensin II (Ang II)
immunostaining was detected in tubular and
interstitial infiltrating cells.
Fig. 2. Spearman correlation between the
expression of transforming growth factor-
(TGF-) mRNA by in situ hybridization, and
-smooth muscle actin by immunohistochem-
istry in progressive membranous nephropathy
(MN). Staining score is expressed as density/
mm2. Magnification 400. Strong up-regula-
tion of tubular TGF- mRNA and interstitial
myofibroblastic activity in progressive MN.
Immunohistochemical staining for -smooth
muscle actin denotes interstitial myofibroblasts.
The different techniques were done as de-
scribed in Methods. Figure shows serial sections
of a representative case. r  0.8, P  0.01.
Interstitial cell infiltration and fibrosis were classified
into 4 groups according to their extent and the presence
of tubular atrophy and degeneration: normal; involve-
ment up to 25%; 26 to 50%; and extensive damage in-
volving more than 50% of the cortex. Interstitial fibro-
sis was defined by the presence of interstitial collagen
determined by Masson technique. Staining for -smooth
muscle actin (-SMA) was particularly prominent in
areas of fibrosis around atrophic tubules, defining vascu-
lar smooth muscle cells, activated mesangial cells, and
interstitial myofibroblasts.
Statistical analysis
Statistical analyses were performed with the GraphPad
Instat and GraphPad Software (San Diego, CA, USA).
Results of the clinical data are expressed as mean 	 SD.
The intensity score and distribution of staining in the
different techniques employed (IHC and ISH) are ex-
pressed as the mean 	 SEM. Mann-Whitney test was
used to compare unpaired groups, Spearman’s correla-
tion was used for the tubular TGF- and PDGF mRNAs
with the interstitial -SMA over-expression. Fisher’s test
was used when appropriate. A P value of 0.05 was
considered significant.
RESULTS
Local RAS is activated in MN
In normal kidneys, ACE immunostaining was only
found in the brush border membrane of tubular cells. In
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Fig. 3. Spearman correlation between the
expression of platelet-derived growth factor
(PDGF)-BB mRNA by in situ hybridization,
and -smooth muscle actin by immunohisto-
chemistry in progressive membranous ne-
phropathy (MN). Staining score is expressed
as density/mm2. Magnification 400. Strong
up-regulation of tubular PDGF mRNA and
interstitial myofibroblastic activity in progres-
sive MN. Immunohistochemical staining for
-smooth muscle actin denotes interstitial my-
ofibroblasts. The different techniques were
performed as described in Methods. Figures
show serial sections of a representative case.
r  0.6, P  0.01.
samples from MN patients, a marked increase in ACE
staining in this region was observed (Fig. 1A). In addi-
tion, a positive staining for ACE appeared in interstitial
cells (Fig. 1B), mainly in -actin–positive cells in sections
of patients with progressive disease (Fig. 1C). We further
determined whether local Ang II production was ob-
served in MN. In the normal kidney, Ang II immuno-
staining was not expressed, while in MN there was a
remarkable increase in Ang II production in tubular
and interstitial infiltrating cells, mainly in progressive
patients, as observed in Figure 1D.
Profibrogenic cytokines (TGF- and PDGF-BB)
are up-regulated in MN by ISH
In kidneys of MN patients, mRNA expression of the
TGF- was up-regulated mainly in cortical tubular epi-
thelial cells (Fig. 2), and this expression was significantly
higher in the group with progressive disease (mRNA
TGF- staining score was 5425 	 1244 in progressive
vs. 800 	 295 in non-progressive MN, P  0.01). No
mRNA expression was found in control kidneys and in
MCD. In general, the TGF- mRNA expression was
increased in the tubulointerstitial area, in a manner con-
sistent with the severity of the disease, and particularly
in tubules surrounded by -actin–positive cells, as ob-
served in the IHC coupled with ISH. At the glomerular
level, we found a weak expression of this growth factor
in some patients.
Platelet-derived growth factor mRNA expression was
consistent with the expression of TGF- and was ob-
served mainly in cortical tubular epithelial cells, and
primarily in cases with progressive disease (9 out of 11
vs. 3 out of 9, P  0.01; mRNA staining score, 3350 	
611 vs. 483 	 310) (Fig. 3).
Interstitial myofibroblast infiltration in MN
-Smooth muscle actin interstitial positive cells were
mainly detected in patients with a progressive disease
(11 out of 11 progressive vs. 3 out of 9 non-progressive,
P  0.01; staining score, 886 	 105 vs. 208 	 55) (Figs.
2 and 3). The staining distribution was mainly in the
peritubular and periglomerular cortical interstitium, and
there was a stronger expression in patients with progres-
sive disease. The presence of myofibroblasts was strongly
correlated with tubular over-expression of TGF- (r 
0.8, P  0.01) and PDGF (r  0.6 P  0.01), as shown
in Figures 2 and 3. Moreover, the presence of myofibro-
blasts was significantly associated with the tubular inter-
stitial cell infiltration and interstitial fibrosis (P  0.05).
In a double IHC to -SMA coupled with ISH for TGF-
performed in some progressive cases, the immunostain-
ing for -SMA was observed mainly in the peritubu-
lar interstitium and in some tubular cells, and TGF-
mRNA expression localized in the surrounding tubular
epithelial cells (Fig. 4).
Furthermore, there was a clear co-localization of inter-
stitial ACE-positive cells, and myofibroblasts, as is shown
in Figure 1C. Isolated glomerular -actin–positive cells
were observed and not associated with a higher incidence
of glomerulosclerosis. In normal kidneys and sections of
MCD, positive staining for -actin only was observed
constitutively in afferent arteriolar walls.
Correlation of renal RAS components and
profibrogenic parametes in MN
In serial sections of different cases of progressive MN,
the ACE over-expression and neoinduction were posi-
tively correlated with the tubular expression of TGF-
and PDGF, as well as with the interstitial infiltration and
myofibroblast activation.
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Fig. 4. Tubular epithelial myofibroblast transdifferentiation in pro-
gressive membranous nephropathy (MN). Immunohistochemistry for
-actin, coupled with in situ hybridization for transforming growth
factor- (TGF-) resulted in a marked increase in TGF-1 tubular
expression in areas with interstitial fibrosis, including tubules with phe-
notypic changes expressing -smooth muscle actin (-SMA) associated
with disruption of the tubular basement membrane.
DISCUSSION
The tubulointerstitial injury is a major feature of MN
and an important predictor of renal dysfunction. Our
study reveals that renal biopsies from patients with MN
present elevated levels of RAS components (increased
ACE and Ang II expression in tubular and interstitial
cells). Our current data also show a strong increase of tu-
buloepithelial cells expressing TGF- and PDGF-BB
mRNAs, which significantly correlates with the degree
of tubulointerstitial damage and with the presence of in-
terstitial myofibroblasts (-SMA–positive cells). These
parameters were correlated with the magnitude of pro-
teinuria and the interstitial cell infiltration, particularly
observed in patients with progressive membranous ne-
phropathy.
The increased trafficking of proteins through the tubu-
lar cells can activate NFB and AP-1 and augment the
tubular expression of target genes associated with inter-
stitial cell infiltration and tubulointerstitial damage [7].
In addition, proteinuria may have a role in the intrarenal
activation of RAS, as it was observed in an animal model
of intense proteinuria and interstitial nephritis induced
by protein overload [11]. In this study, a significant in-
crease in angiotensinogen and ACE mainly localized in
proximal and distal tubules and in the glomeruli was
observed [11]. In our study, we observed an increase
in tubular ACE and Ang II expression compared with
controls; however, ACE neoinduction was also observed
in renal myofibroblasts, and Ang II was localized in the
interstitial inflammatory cells, thus contributing to the
perpetuation of damage (Fig. 5). In a model of fibrosing
kidney, interstitial fibroblast-like cells express RAS com-
ponents [17], and production of Ang II by interstitial
Fig. 5. In patients with membranous nephropathy (MN), there was
an angiotensin-converting enzyme (ACE) and angiotensin II (Ang II)
switched expression from tubular epithelial cells to interstitial cells
coinciding with an activation of myofibroblasts, and recruitment of
interstitial mononuclear cells, suggesting an additional novel participa-
tion of Ang II as a mediator of tubulointerstitial injury.
immunocompetent cells has also been described in ex-
perimental models of salt-sensitive hypertension [14],
supporting our observations in human pathology of MN.
The finding of important tubulointerstitial lesions in
nephropathies with persistent proteinuria suggests that
mediators generated in tubular cells could be involved
in this process. Locally generated Ang II could be se-
creted to the interstitial space, inducing the vasoconstric-
tion of peritubular vessels with subsequent ischemia. In
addition, Ang II could activate renal interstitial fibro-
blasts, inducing several growth-related metabolic events
mediated by the AT1 receptor [10]. Furthermore, there is
ample evidence in vivo and in vitro that Ang II activates
NFB and up-regulates NFB-related genes [12, 13, 18].
The final step in renal disease progression is atrophy
and fibrosis of renal parenchyma. Transforming growth
factor-1 and PDGF are two of the main profibrogenic
cytokines. Numerous studies have shown that Ang II
stimulates the expression of TGF-1 gene and protein in
the kidney, thereby establishing the link between Ang II
and fibrosis [3, 19–21]. In renal diseases in which there is
a local activation of the RAS, even in the absence of sys-
temic or intraglomerular hypertension, TGF-1–induced
fibrosis may be via an Ang II–dependent mechanism [9].
Supporting our findings, a recently published study in
the remnant kidney model in rats, by using morphologic
techniques, showed an association between tubular pro-
tein load, peritubular accumulation of macrophages and
myofibroblasts, and TGF-1 expression [22]. Interest-
ingly, the RAS inhibition with an ACEI prevented pro-
teinuria, as well as the inflammatory and fibrogenic re-
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action [22]. Complementary to these findings is the hypoth-
esis that tubular epithelial cells can transdifferentiate to
a mesenchymal phenotype, migrate to the interstitium,
and behave as true fibroblasts [23]. A recently published
study addressed this problem and presented evidence
suggesting that, via transition to a mesenchymal pheno-
type, tubular epithelial cells can produce extracellular
matrix proteins in human disease and directly participate
in the fibrotic process [24]. Myofibroblasts, identified by
the expression of -SMA, are the main source of extra-
cellular matrix (ECM), by participating in progressive
tubulointerstitial fibrosis, and are the best prognostic
indicator of disease progression in both human and ex-
perimental glomerulonephritis [6, 25].
Possible mechanisms involved in tubular epithelial-
myofibroblast transdifferentiation have been reviewed
very recently [26], and TGF- and PDGF-BB are able to
induce transformation of fibroblasts into myofibroblasts
[27, 28], supporting the strong correlation observed in
this study.
This hypothesis has been supported by evidence in the
model of 5/6 nephrectomy in rats, in which the tubular
epithelial cells expressed -SMA associated with disrup-
tion of the tubular basement membrane and ultrastruc-
tural changes consistent with an epithelial myofibroblast
transdifferentiation [29]. The observation in human glo-
merulonephritis that tubular epithelial-myofibroblast trans-
differentiation occurs in association with up-regulation
of TGF-, destruction of tubular basement membrane,
loss of epithelial marker cytokeratin, and de-novo expres-
sion of -SMA, supports the wide process of tubular epi-
thelial-myofibroblast transdifferentiation [30], as shown
in Figure 4 in a case of progressive MN.
As we noted, TGF- is a key regulator of the tubular
epithelial-myofibroblast transdifferentiation (TEMT) in
different tissues [24, 31, 32], and recent studies have
shown that TGF- regulates TEMT through its intracel-
lular signaling pathway, Smad2 [33]. TGF-–induced
Smad2 phosphorylation results in the transformation of
tubular epithelial cells into a myofibroblast phenotype
with the loss of E-cadherin and de novo expression of
-SMA and collagens in normal rat tubular epithelial
cells [34]. In addition, Smad signaling has been described
as a novel pathway of Ang II–induced renal fibrosis by
inducing TEMT mediated by the AT1 receptor [35].
CONCLUSION
In patients with MN there was an ACE-switched ex-
pression from tubular epithelial cells to interstitial cells
coinciding with an activation of myofibroblasts, sug-
gesting an additional novel participation of Ang II as a
mediator of tubulointerstitial injury.
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